Uromitexan
Generic Name
Uromitexan 400 mg Injection
Manufacturer
Baxter International Inc.
Country
Germany
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| uromitexan 400 mg injection | ৳ 215.61 | N/A |
Description
Overview of the medicine
Mesna is a sulfhydryl compound used to prevent hemorrhagic cystitis caused by oxazaphosphorine cytostatics like ifosfamide and cyclophosphamide.
Uses & Indications
Dosage
Adults
Typically, the total daily dose of Mesna is 60% of the ifosfamide or cyclophosphamide dose, divided into three equal bolus injections (20% each) given at 0, 4, and 8 hours after the cytostatic.
Elderly
No specific dosage adjustment based on age alone; consider renal function.
Renal_impairment
No specific dosage adjustment recommended for Mesna itself, but careful monitoring may be advisable due to underlying disease or co-medications.
How to Take
Uromitexan 400 mg Injection is administered intravenously by a healthcare professional. It can be given as a bolus injection or as a continuous infusion. It should be given with appropriate timing relative to the chemotherapy agent.
Mechanism of Action
Mesna binds to and detoxifies urotoxic metabolites, particularly acrolein, produced by oxazaphosphorine cytostatics in the urinary tract, preventing bladder toxicity.
Pharmacokinetics
Onset
Rapid, typically within minutes of intravenous administration.
Excretion
Primarily renal; approximately 60-80% excreted within 24 hours as mesna or dimesna.
Half life
Parent compound (Mesna): approximately 0.36 hours. Mesna-disulfide (dimesna): approximately 1.12 hours.
Absorption
Administered intravenously, resulting in 100% systemic bioavailability. Rapidly oxidized in plasma to dimesna (mesna disulfide), its major circulating metabolite.
Metabolism
Rapidly oxidized in the plasma to dimesna. Dimesna is then reduced back to free mesna in the kidney tubules.
Side Effects
Contraindications
- •Hypersensitivity to Mesna or other thiol compounds.
- •Known allergic reaction to any component of the formulation.
Drug Interactions
No other significant drug-drug interactions are well-documented.
Mesna's action is localized to the urinary tract.
Oxazaphosphorine cytostatics (e.g., ifosfamide, cyclophosphamide)
Mesna is designed to specifically interact with and detoxify metabolites of these drugs in the urinary tract without interfering with their anti-cancer efficacy.
Storage
Store at room temperature (20-25°C or 68-77°F). Protect from light. Do not freeze. Discard any unused portion.
Overdose
No specific antidote for Mesna overdose. Management involves supportive care and symptomatic treatment.
Pregnancy & Lactation
Pregnancy Category B. Use in pregnancy only if clearly needed and the potential benefits outweigh the risks. It is unknown if Mesna is excreted in human milk; caution should be exercised when administered to a nursing woman.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Varies by manufacturer, generally 2 to 3 years when stored as recommended. Once opened, use immediately.
Availability
Hospitals, Clinics, Specialized pharmacies
Approval Status
Approved by major regulatory bodies (e.g., FDA, EMA)
Patent Status
Generic available
WHO Essential Medicine
YesAlternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine
More Medicines
Explore other medicines you might be interested in